Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Medpace Securities Fraud Lawsuit
Business securities fraud

Medpace Securities Fraud Lawsuit

Analysis based on 42 articles · First reported Apr 24, 2026 · Last updated May 08, 2026

Sentiment
-70
Attention
4
Articles
42
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the alleged securities fraud by Medpace, leading to significant stock price declines. Investors in Medpace are facing losses, and the ongoing class action lawsuit by Bleichmar Fonti & Auld LLP creates uncertainty for the company's future.

Biotechnology Pharmaceutical Medical Device
Event Summary

Medpace, a clinical contract research organization, is facing a class action lawsuit filed by Bleichmar Fonti & Auld LLP for allegedly misleading investors. The lawsuit, pending in the United States — United States District Court for the Northern District of California, claims Medpace understated cancellation rates and overstated its book-to-bill ratio for 4Q 25. This alleged misconduct led to a nearly 16% stock drop on February 9, 2026, after Medpace released its 4Q 2025 financial results, reporting a book-to-bill ratio decline to 1.04 due to elevated cancellations. Further investigations by Bleichmar Fonti & Auld LLP suggest cancellations continued to increase, and the book-to-bill ratio declined to 0.88 for 1Q 26, causing another 23% stock decline on April 23, 2026. Additionally, Medpace's President, Jesse Geiger, announced his intention to resign.

Key Actions
100 Bleichmar Fonti & Auld LLP filed class action lawsuit Medpace
100 Medpace experienced stock drop
92 Medpace made false statements
90 Medpace released financial results
70 Jesse Geiger announced intention to resign Medpace
Entities Involved
stock
Medpace
Medpace is facing a class action lawsuit for allegedly misleading investors about its cancellation rates and book-to-bill ratio, leading to significant stock drops. The company's stock declined nearly 16% on February 9, 2026, and an additional 23% on April 23, 2026.
Importance 100 Sentiment -75
priv
Bleichmar Fonti & Auld LLP
Bleichmar Fonti & Auld LLP is the leading securities law firm that filed the class action lawsuit against Medpace and is encouraging investors to join the suit.
Importance 90 Sentiment 60
per
Jesse Geiger
Jesse Geiger, the President of Medpace, announced his intention to resign amidst the ongoing investigations and stock declines.
Importance 70 Sentiment -55
govactor
United States — United States District Court for the Northern District of California
The class action lawsuit against Medpace Holdings Inc. is pending in the United States — United States District Court for the Northern District of California.
Importance 50 Sentiment 0
stock
Tesla, Inc.
Tesla, Inc. is mentioned as a past client of Bleichmar Fonti & Auld LLP, where the firm recovered over $900 million in value from its Board of Directors.
Importance 0 Sentiment 0
stock
Sun Pharma
Sun Pharma is mentioned as a past client of Bleichmar Fonti & Auld LLP, where the firm recovered $420 million.
Importance 0 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.